Added to YB: 2026-02-10
Pitch date: 2026-02-06
GOSS [neutral]
Gossamer Bio, Inc.
-7.05%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Market Cap
$523.1M
Pitch Price
$2.27
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.62
P/E
-3.29
EV/Sales
12.39
Sector
Biotechnology
Category
N/A
Biotech Catalysts on My Radar | February 2026 - Gossamer Bio, Inc.
GOSS (quick overview): Clinical biotech targeting pulmonary arterial hypertension with inhaled seralutinib. Feb 2026 Phase 3 PROSERA topline (~390 patients) tests disease-modifying approach vs standard care. Primary endpoint: 6-min walk distance improvement. Positive data validates first-in-class status; negative undermines remodeling thesis. $570M mcap at $2.46.
Read full article (2 min)